Omidria

Eye Pain, Inflammation, corneal refractive surgery + 20 more

Treatment

2 FDA approvals

20 Active Studies for Omidria

What is Omidria

Ketorolac

The Generic name of this drug

Treatment Summary

Phenylephrine is a drug used to treat low blood pressure, widen the pupil, and narrow blood vessels. It was first described in literature in the 1930s and was approved for use by the FDA in 1939. It is often referred to by its brand name Neo-Synephrine.

Toradol

is the brand name

image of different drug pills on a surface

Omidria Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Toradol

Ketorolac

1991

316

Approved as Treatment by the FDA

Ketorolac, also called Toradol, is approved by the FDA for 2 uses like caudal epidural block therapy and induction of Nerve Block .

caudal epidural block therapy

Used to treat caudal epidural block therapy in combination with Bupivacaine

induction of Nerve Block

Used to treat induction of Nerve Block in combination with Bupivacaine

Effectiveness

How Omidria Affects Patients

Phenylephrine is a medicine that increases blood pressure, widens the pupils, and causes blood vessels to narrow. Eye drops containing the medicine can last for 3-8 hours, while intravenous solutions have a shorter effect, lasting about 5 minutes and 2.5 hours respectively. People taking eye drops should be aware of the risk of abnormal heart rhythms, high blood pressure, and eye pupil shrinkage. People taking intravenous solutions should be aware of the risk of slow heart rate, allergic reactions, injury to tissue, and the need to avoid taking other medicines that cause contractions.

How Omidria works in the body

Phenylephrine is a drug that causes blood vessels to narrow. This leads to an increase in blood pressure, as well as a decrease in heart rate. It works by activating alpha-1 adrenergic receptors, which are responsible for these effects.

When to interrupt dosage

The endorsed dosage of Omidria is contingent upon the determined condition, including Nasal Congestion, Sinus pressure and Pain. The measure of dosage changes as per the technique of administration (e.g. Tablet - Oral or Gel - Rectal) noted in the table below.

Condition

Dosage

Administration

Macular Edema, Cystoid

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

Miosis disorder

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

Seasonal Allergic Conjunctivitis

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

Cataract Surgery

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

induction of Local Anaesthesia

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

Ocular Itching

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

Eye Pain

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

Intraocular Lens Replacement

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

Macular Edema, Cystoid

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

postoperative ocular pain

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

Pain

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

caudal epidural block therapy

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

Macular Edema

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

Acute Coryza

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

Pupil

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

induction of Nerve Block

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

Pericarditis Acute

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

Inflammation

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

corneal refractive surgery

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

Induced Hyperthermia

, 5.0 mg/mL, 4.5 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 10.0 mg, 15.75 mg, 4.0 mg/mL, 5.0 mg, 60.0 mg/mL, 0.5 %, 0.4 %, 0.45 %, 2.88 mg/mL, 0.4 mg/mL, 40.0 mg/mL, 3.0 mg/mL, 9.0 mg/mL, 50.0 mg/mL, 45.0 mg/mL, 0.5 mg/mL, 10.0 mg/mL

Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, , Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, Tablet, film coated - Oral, Oral, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection - Intramuscular, Tablet, Tablet - Oral, Solution, Solution - Ophthalmic, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Liquid, Liquid - Intramuscular, Solution - Intramuscular, Injection, solution, concentrate - Intraocular, Injection, solution, concentrate, Intraocular, Kit - Epidural; Infiltration; Intramuscular; Intravenous, Epidural; Infiltration; Intramuscular; Intravenous, Kit, Infiltration; Intramuscular; Intravenous; Topical, Kit - Infiltration; Intramuscular; Intravenous; Topical, Injection, solution - Ophthalmic, Injection, solution - Intraocular, Topical, Spray, metered - Topical, Epidural; Infiltration; Intramuscular; Intravenous; Topical, Kit - Epidural; Infiltration; Intramuscular; Intravenous; Topical, Solution, concentrate, Solution, concentrate - Intraocular; Irrigation, Intraocular; Irrigation, Kit - Ophthalmic

Warnings

Omidria Contraindications

Condition

Risk Level

Notes

Heart failure

Do Not Combine

Hyperkalemia

Do Not Combine

Renal Insufficiency

Do Not Combine

Hemorrhagic Disorders

Do Not Combine

Kidney Failure

Do Not Combine

A History of Gastric or Duodenal Ulcers

Do Not Combine

Liver Diseases

Do Not Combine

Major Surgery

Do Not Combine

Pulse Frequency

Do Not Combine

Gastrointestinal Hemorrhage

Do Not Combine

Crohn's Disease

Do Not Combine

suspected cerebrovascular bleeding

Do Not Combine

active Gastrointestinal Bleeding

Do Not Combine

NSAID-Induced Asthma

Do Not Combine

Severe Hepatic Impairment

Do Not Combine

incomplete hemostasis

Do Not Combine

Coronary Artery Bypass Grafting

Do Not Combine

Gastrointestinal Perforation

Do Not Combine

Pulse Frequency

Do Not Combine

Hemorrhage

Do Not Combine

Peptic Ulcer

Do Not Combine

Pulse Frequency

Do Not Combine

Labour

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Third trimester of pregnancy

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Ketorolac may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Ketorolac may interact with Pulse Frequency

There are 20 known major drug interactions with Omidria.

Common Omidria Drug Interactions

Drug Name

Risk Level

Description

Aceclofenac

Major

The risk or severity of adverse effects can be increased when Ketorolac is combined with Aceclofenac.

Acemetacin

Major

The risk or severity of adverse effects can be increased when Ketorolac is combined with Acemetacin.

Acetylsalicylic acid

Major

The risk or severity of adverse effects can be increased when Ketorolac is combined with Acetylsalicylic acid.

Alclofenac

Major

The risk or severity of adverse effects can be increased when Ketorolac is combined with Alclofenac.

Alminoprofen

Major

The risk or severity of adverse effects can be increased when Ketorolac is combined with Alminoprofen.

Omidria Toxicity & Overdose Risk

If someone takes too much phenylephrine, they may experience headaches, high blood pressure, slow heart rate, tingling in the extremities, and a feeling of pressure in the head. Treatment for an overdose may involve stopping the drug, supportive care, and administering phentolamine under the skin to prevent leakage into surrounding tissue.

image of a doctor in a lab doing drug, clinical research

Omidria Novel Uses: Which Conditions Have a Clinical Trial Featuring Omidria?

81 active trials are currently investigating the potential of Omidria to alleviate Hay Fever, Headaches and Laryngotracheitis.

Condition

Clinical Trials

Trial Phases

Inflammation

55 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 3, Phase 4

Induced Hyperthermia

0 Actively Recruiting

caudal epidural block therapy

5 Actively Recruiting

Not Applicable, Phase 4, Phase 3, Phase 2

Intraocular Lens Replacement

0 Actively Recruiting

Acute Coryza

0 Actively Recruiting

Macular Edema, Cystoid

0 Actively Recruiting

induction of Nerve Block

0 Actively Recruiting

Pupil

0 Actively Recruiting

Local Anaesthesia therapy

0 Actively Recruiting

corneal refractive surgery

0 Actively Recruiting

Seasonal Allergic Conjunctivitis

0 Actively Recruiting

Eye Pain

0 Actively Recruiting

postoperative ocular pain

0 Actively Recruiting

Eye

0 Actively Recruiting

Ocular Itching

0 Actively Recruiting

Pericarditis Acute

1 Actively Recruiting

Phase 2, Phase 3

Miosis disorder

0 Actively Recruiting

Macular Edema, Cystoid

0 Actively Recruiting

Macular Edema

1 Actively Recruiting

Phase 1, Phase 2

Cataract Surgery

3 Actively Recruiting

Not Applicable

Omidria Reviews: What are patients saying about Omidria?

5

Patient Review

3/2/2016

Omidria for Postoperative Pain in Eye

5

Patient Review

3/2/2016

Omidria for Dilated Pupils During Eye Surgery

5

Patient Review

5/2/2016

Omidria for Dilated Pupils During Eye Surgery

5

Patient Review

10/19/2016

Omidria for Dilated Pupils During Eye Surgery

Patient Q&A Section about omidria

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is OMIDRIA covered by Medicare?

"The Centers for Medicare & Medicaid Services (CMS) reimburse OMIDRIA separately when it is used in ambulatory surgery centers (ASCs). OMIDRIA is reimbursed per mL. Providers should use 1 mL as the billing unit and bill for 4 units when a full vial of OMIDRIA is utilized."

Answered by AI

What is OMIDRIA used for?

"OMIDRIA is a prescription medication that is used during cataract surgery in order to help keep the pupil dilated and to decrease eye pain afterwards."

Answered by AI

Where can I buy OMIDRIA?

"The drug OMIDRIA is available for purchase from national wholesalers, specialty distributors, and McKesson Plasma and Biologics. For customers of the McKesson full-line wholesaler division, OMIDRIA is available for purchase through McKesson Specialty Distribution."

Answered by AI

Clinical Trials for Omidria

Image of Montana State University in Bozeman, United States.

Haskap Berries for Exercise Performance Recovery

18 - 35
All Sexes
Bozeman, MT

The purpose of this clinical trial is to determine how certain food items affect oxidative stress, inflammation, and performance recovery from exercise induced muscle damage in a resistance trained population. The main questions The investigators aim to answer are the following: * Do Haskaps speed the recovery of oxidative stress and inflammation markers after an intense lower body workout in resistance trained adults? * Do Haskaps speed the recovery of performance measures after an intense lower body workout in resistance trained adults? * The data collected in this investigation may also be used to ask additional questions not yet identified. For example, the investigators may use the stored samples to evaluate how the blood metabolites of participants differ before and after intense exercise. These additional questions are called secondary analyses. Please note that no genetic analysis will be conducted and racial and ethnic differences among participants will not be used in any secondary analyses. Researches will compare Haskap juice to a color, flavor and carbohydrate matched placebo to see if Haskaps speed recovery in inflammation, oxidative stress and performance. * Participants will be asked to drink either Haskap juice or placebo and follow a low polyphenolic diet * Participants will perform an intense resistance workout * Participants will have their blood drawn before and after the workout * Performance will be analyzed at 24, 48 and 72 hours after the workout

Recruiting
Paid Trial

Montana State University

Mary P Miles

Image of Byers Eye Institute in Palo Alto, United States.

LLM-Based Education for Cataract Surgery

18+
All Sexes
Palo Alto, CA

Patients with cataracts disease need to choose what type of artificial lens will go into their eye prior to surgery date. Some lenses are standard and are usually covered by insurance. Other "premium" lenses have various benefits such as reducing the need for glasses but usually require out-of-pocket costs. The combined busy outpatient clinic and complexity of artificial lens choices in the ever-changing world of cataract surgery tends to lead patients confused about their available lens options. There is an abundance of educational material present in premium lenses, however these are limited by accessibility and are standardized at single educational levels. Therefore in the present study, we want to test whether giving patients a short LLM powered AI-guided explanation from Custom GPT from OpenAI of lens options prior to their consultation with their doctor can improve visit efficiency, physician explanation and patient understanding of lens options. We will compare two groups: standard of care versus standard of care plus AI education. The LLM in this study is intended to provide supplemental information about premium intraocular lens(IOLs) options to study participants, and is no means supposed to replace a health care professional in the diagnosis, cure, treatment, and/or mitigation of disease. Study is analogous to giving a verified health pamphlet to a patient for them to view and learn different IOL options, in other words, facilitating patient understanding of their options. The LLM will be trained by several health care professionals and MD specialists to provide sufficient instructions. Sources will include verified online resources and MD information. The investigators hope to learn if a large language model-based educational tool can improve visit efficiency, physician explanation and patient understanding of intraocular lens options. New knowledge of this study could guide how cataract counseling is delivered in the future and may help clinics spend more time on individualized questions instead of repeating generic information.

Waitlist Available
Has No Placebo

Byers Eye Institute

Robert T Chang, MD

Image of University of New Brunswick in Fredericton, Canada.

Mediterranean Diet for Toddler Health

24 - 36
All Sexes
Fredericton, Canada

Toddlerhood (ages 2-3) is a critical window when the gut microbiome is still developing and eating habits are being established. Yet, many Canadian toddlers eat diets high in sugar and salt, which may affect long-term health. This study will test whether a MED diet can improve dietary inflammation, gut health, and body composition in toddlers and whether a tailored nutrition education program for parents can help families maintain healthy eating patterns. In this study, toddlers will be randomly assigned to a 3-week MED diet or their usual diet. Families in the MED diet group will receive free meal boxes for the 3 weeks, plus guidance from a nutrition researcher through a structured education program. The standard diet group will continue their regular diet with general nutrition advice. Researchers will collect dietary information, body composition assessments, and stool samples to measure gut microbiome composition and metabolites. This first study of a controlled diet intervention in toddlers, combining behavioral support, high-quality food provision, and advanced gut microbiome analysis, will help understand how early diet shapes lifelong eating habits and health, guiding public health strategies and precision nutrition approaches to prevent chronic disease from early life.

Waitlist Available
Has No Placebo

University of New Brunswick

Dr. Maryam Kebbe, PhD, CLC

Have you considered Omidria clinical trials?

We made a collection of clinical trials featuring Omidria, we think they might fit your search criteria.
Go to Trials
Image of McGill University Health Centre in Montreal, Canada.

Dexmedetomidine for Pain Relief

18 - 75
All Sexes
Montreal, Canada

This study will compare three different doses of perineural dexmedetomidine 0.67 mcg/kg, 1 mcg/kg, and 1.33 mcg/kg as adjuvants to local anesthetics for ultrasound-guided infraclavicular brachial plexus blocks (ICBs). Our research hypothesis is that 1.33 mcg/kg will provide a 15%-longer duration than 1mcg/kg, which in turn will provide a 15%-longer duration than 0.67 mcg/kg. Since analgesic duration and sensory duration can be influenced by intake of pain medications and surgical trauma to small cutaneous nerves, respectively, we will select motor block duration as the main outcome to better target the action of dexmedetomidine on the brachial plexus.

Phase 2
Recruiting

McGill University Health Centre

Julián Aliste, MD

Image of University of California, San Francisco in San Francisco, United States.

Vision Centers for Eye Care

Any Age
All Sexes
San Francisco, CA

The goal of this clinical trial is to evaluate the effect of vision centers on access to eye care and eye health outcomes in South Asia. The main questions it aims to answer are: 1. Do vision centers increase visits to eyecare centers? 2. Do vision centers increase spectacle ownership and wearing? 3. Do vision centers improve visual acuity of the population? Researchers will compare outcomes in communities randomized to have a vision center is established with communities randomized to delay establishment of a vision center. Outcomes will be assessed through population-based surveys at baseline and after two years as well as through hospital records collected throughout the study period.

Waitlist Available
Has No Placebo

University of California, San Francisco

Kieran O'Brien, PhD, MPH

Image of UConn Health in Farmington, United States.

Cognitive Remediation for Memory and Thinking Difficulties

18+
All Sexes
Farmington, CT

The goal of this clinical trial is to determine if a neuroscience-based computerized cognitive remediation ("brain training") program can treat neurocognitive dysfunction (i.e., memory or thinking difficulties) that emerges in some older adults following a viral infection. The main questions it aims to answer are: * Does computerized cognitive remediation improve cognitive performance and day-to-day functioning in older adults with postviral neurocognitive dysfunction? * Will treatment effects be maintained over time, leading to better long term cognitive outcomes? * Does the treatment lead to reductions in blood-based markers of inflammation as a potential mechanism of cognitive symptom improvement? * Can the treatment be optimized and refined based on feedback from participants to improve user (patient) experience? Researchers will compare the computerized cognitive remediation program to an active computer-based control condition (alternative computer activities) to see if the computerized cognitive remediation program works to treat postviral neurocognitive dysfunction. Participation takes approximately 43-48 hours over 7 months, with most activities (40-46 hours) completed within the first 7-8 weeks, including: * Initial intake visit: Eligibility confirmation (\~2-3 hours) * Computer activities: About 5 hours per week for \~6 weeks (total \~30 hours) completed on a computer tablet provided by the study and loaned to participants for use during the treatment phase * Weekly remote check-in meetings: \~30 minutes each during treatment * Blood draws: Two sessions (before and after treatment), \~20-30 minutes each * Three research visits: Pre-treatment, post-treatment, and 6-month follow-up (\~2-3 hours each, including assessments of cognitive, emotional, and daily functioning)

Waitlist Available
Has No Placebo

UConn Health

Cutter Lindbergh, Ph.D.

Have you considered Omidria clinical trials?

We made a collection of clinical trials featuring Omidria, we think they might fit your search criteria.
Go to Trials
Image of Mount Sinai Hospital in Toronto, Canada.

Intrathecal Morphine for Urinary Retention

18+
All Sexes
Toronto, Canada

Revision total knee arthroplasty (rTKA) is a frequently performed procedure. Adequate pain management is an important feature, especially for fast-track and Enhanced Recovery After Surgery (ERAS) programs. The multimodal approach, including single shot or continuous nerve blocks with catheters and spinal or epidural morphine, is a stablished strategy. Although the administration of intrathecal morphine (IM) has been shown to significantly reduce pain scores, it is not free of adverse effects. Postoperative urinary retention (POUR) is possible and might increase the risk of periprosthetic infection. The purpose of this study is to compare patients undergoing rTKAS under spinal anesthesia with IM to patients undergoing the same procedure, under the same anesthetic technique, but with no IM, for POUR and postoperative pain related outcomes. All patients will have single shot and continuous adductor canal block (CACB) and single shot IPACK (interspace between the popliteal artery and the posterior knee capsule) block. The hypothesis is that postoperative pain control is comparable between the groups, with lower incidence of POUR in patients with no IM given.

Phase 3
Recruiting

Mount Sinai Hospital

Hermann dos Santos Fernandes, MD, PhD

Image of Abcentra Investigational Site in Los Angeles, United States.

Orticumab for Heart Attack

18+
All Sexes
Los Angeles, CA

The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies

Phase 2
Recruiting

Abcentra Investigational Site (+6 Sites)

Abcentra

Image of School of Public Health in Bloomington, United States.

High Salt Intake for High Blood Pressure

60 - 85
All Sexes
Bloomington, IN

Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs blood pressure control by affecting systemic blood vessels and the kidneys. These changes contribute to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. Salt is particularly deleterious in older adults who are more likely to exhibit salt-sensitive hypertension. However, salt consumption remains high in the United States. Thus, there is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. Limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally, published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans' protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high-dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury/impaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could facilitate novel therapeutic targets to combat high salt.

Recruiting
Has No Placebo

School of Public Health

Have you considered Omidria clinical trials?

We made a collection of clinical trials featuring Omidria, we think they might fit your search criteria.
Go to Trials